| Literature DB >> 32127759 |
S Ramadevi1, B Kaleeswaran2, S Ilavenil3, Akilesh Upgade4, D Tamilvendan5, R Rajakrishnan6, A H Alfarhan6, Y-O Kim7, H-J Kim8.
Abstract
Pedalium murex L. is a medicinal herb that has been used for the treatment of diseases related to kidney in the traditional system of medicine. The current study aims to study the effect of ethyl acetate extract of P. murex (EAEP) and its fractionated compound pedalitin against urease production and UreC gene expression in Proteus mirabilis. The selected reference strain Proteus mirabilis (MTCC 425) and the isolates culture of Proteus mirabilis were subjected to study the antibacterial efficacy of P. murex. Expression analysis of P. mirabilis urease gene was successfully done by QPCR. The ethyl acetate extract effectively inhibit the reference Proteus mirabilis and bacterial isolates of Proteus mirabilis in the clinical samples studied. EAEP has showed more potent activity (56.7%) against urease enzyme and pedalitin also exhibited potent activity (30.1%). Using qPCR, the expression of UreC gene of P. mirabilis was controlled by EAEP and also its bioactive compound pedalitin. The present study clearly demonstrated the potency of P. murex in controlling the growth of pathogenic P. mirabilis and to control the expression of urease enzyme production as well as to restrict the urease gene expression in P. mirabilis.Entities:
Keywords: Pedalitin; Pedalium murex; Proteus mirabilis; UreC; qPCR
Year: 2020 PMID: 32127759 PMCID: PMC7042614 DOI: 10.1016/j.sjbs.2020.01.014
Source DB: PubMed Journal: Saudi J Biol Sci ISSN: 1319-562X Impact factor: 4.219
Pedalium murex L.: Plant description and its medicinal value.
| S. No | Description | Prediction of plant | |
|---|---|---|---|
| Pedaliaceae | |||
| Yaanainerinji | |||
| Medicinal uses | References | ||
| Urinary problem, urinary calculi, urinary troubles, dieurtic, male fertility disorder, leucorrhoea, | |||
| Diabetes, demulcent, antispasmodic and aphrodisiac, Gonorrhoea | |||
| Incontinence of urine, urinary calculi, Strangury | |||
| Ulcers, dysuria, Bone fracture, diarrhea, splenic enlargement, diabetes, Gonorrhoeal rheumatism, Aphrodisiac, Demulcent | |||
| anti-bilious, calm body heat, virility, Pousthik | |||
| Leucorrhoea, urinary tract disorders, diuretic property, joint pain & lumbago, bladder troubles and gonorrhea | |||
| Spermatorrhoea, Dysuria, Ardorurinae, Gonorrhoea | |||
Urease enzyme assay using Weatherburn method.
| S. No | Inhibitory agents | Concentration ml | Extract ml | Urease enzyme from | Phosphate buffer ml | Urea ml | Phenol reagent ml | Alkali reagent ml |
|---|---|---|---|---|---|---|---|---|
| EAEP | 1% | 0.1 | 0.2 | 1.2 | 0.5 | 1 | 1 | |
| Pedalitin | 1% | 0.1 | 0.2 | 1.2 | 0.5 | 1 | 1 | |
| Thiourea | 1% | 0.1 | – | 1.2 | 0.5 | 1 | 1 |
Fig. 1Chemical process of urease producing bacteria; S = negatively charged sulphate group, GAG = glycoaminoglycan layer, = components of urine.
Antibacterial activity of standard antibiotics against Proteus mirabilis (Himedia - Hexa UTI 5) (Zone of inhibition in mm (Mean ± S.D)*).
| S. No | |||||||
|---|---|---|---|---|---|---|---|
| Samples | Antibiotics in disc (Zone of inhibition in mm (Mean ± S.D)*) | ||||||
| Norfloxacin (NX-10 µg) | Ciprofloxacin (CIP −5 µg) | Ampicillin (AMP − 10 µg) | Co-Trimoxazole (COT − 25 µg) | Nitrofurantoin (NIT − 300 µg) | Amoxyclav (AMC − 30 µg) | ||
| 33.3 ± 6.02 | 38.3 ± 2.88 | 16.0 ± 6.0 | 12.6 ± 12.0 | 00 | 00 | ||
| 25.0 ± 2.64 | 26.0 ± 5.50 | 00 | 00 | 00 | 00 | ||
| 22.6 ± 9.29 | 33.6 ± 4.16 | 00 | 00 | 00 | 00 | ||
| 26.6 ± 1.52 | 34.6 ± 1.52 | 00 | 11.6 ± 7.0 | 00 | 00 | ||
| 00 | 00 | 00 | 00 | 00 | 00 | ||
| 17.3 ± 11.0 | 18.3 ± 14.4 | 00 | 00 | 00 | 00 | ||
| 25.3 ± 4.04 | 29.6 ± 0.57 | 12.3 ± 2.51 | 00 | 00 | 10.0 ± 1.0 | ||
| 31.0 ± 1.73 | 32.3 ± 2.51 | 6.66 ± 5.7 | 00 | 00 | 00 | ||
| 16.3 ± 10.1 | 18.6 ± 10.9 | 0 | 00 | 00 | 00 | ||
| 22.0 ± 7.54 | 21.6 ± 10.0 | 0 | 00 | 7.66 ± 2.08 | 00 | ||
Assessment of Antibacterial activity, MBC and MIC of EAEP against clinical isolate P. mirabilis and its reference strains (Zone of inhibition in mm) (Values in µg/ml).
| S. No | Organisms | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical samples (Zone of inhibition in mm (Mean ± S.D)*) | Standard bacteria (Zone of inhibition in mm (Mean ± S.D)*) | |||||||||
| PM5 | MBC | MIC | PM1 | MBC | MIC | MBC | MIC | |||
| 14.3 ± 1.00 | 125 | 125 | 18.6 ± 1.52 | 62.5 | 125 | 20.6 ± 1.15 | 125 | 62 | ||
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
Inhibitory activity of Pedalium murex L. against urease enzyme.
| Test extracts | Urease inhibitory activity (in percentage) |
|---|---|
| 56.7% | |
| 30.1% | |
| 96.3% |
Effect of normal treatment on gene UreC of Proteus mirabilis using qPCR.
| NO | Treatment group | Target urease | House Keeping | References | Mean | SEM | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Control | 16.76 | E11 | SYBR | 16srRNA | 14.75 | 2.01 | 0 | 1.00 | 0.99 ± 0.12 | 0.0446014 | |
| Control | 16.87 | D11 | SYBR | 16srRNA | 14.86 | 2.02 | 0.01 | 1.0 | |||
| Control | 16.52 | D12 | SYBR | 16srRNA | 14.79 | 1.73 | −0.29 | 1.22 | |||
| Control | 16.57 | F11 | SYBR | 16srRNA | 14.83 | 1.75 | 0.02 | 0.99 | |||
| Control | 16.75 | C11 | SYBR | 16srRNA | 14.81 | 1.94 | 0.19 | 0.87 | |||
| Control | 16.87 | A11 | SYBR | 16srRNA | 14.91 | 1.96 | 0.02 | 0.98 | |||
| Control | 16.73 | B11 | SYBR | 16srRNA | 14.87 | 1.86 | −0.11 | 1.08 | |||
| Control | 16.71 | H11 | SYBR | 16srRNA | 14.53 | 2.18 | 0.33 | 0.80 | |||
Effect of EAEP treatment on gene UreC of Proteus mirabilis using qPCR.
| S. No | Treatment Group | Target urease | House Keeping | References | Mean | SEM | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| EAEP | 18.19 | G10 | SYBR | 16srRNA | 15.15 | 3.04 | 1.04 | 0.49 | 0.33 ± 0.09 | 0.0341616 | |
| EAEP | 18.97 | F10 | SYBR | 16srRNA | 15.08 | 3.89 | 1.88 | 0.27 | |||
| EAEP | 18.44 | SYBR | 16srRNA | 14.30 | 4.14 | 2.41 | 0.19 | ||||
| EAEP | 18.30 | B10 | SYBR | 16srRNA | 14.73 | 3.56 | 1.82 | 0.28 | |||
| EAEP | 18.44 | A10 | SYBR | 16srRNA | 14.84 | 3.60 | 1.66 | 0.32 | |||
| EAEP | 18.72 | C10 | SYBR | 16srRNA | 15.03 | 3.69 | 1.73 | 0.30 | |||
| EAEP | 18.25 | E10 | SYBR | 16srRNA | 15.12 | 3.12 | 1.27 | 0.42 | |||
| EAEP | 18.02 | D10 | SYBR | 16srRNA | 14.56 | 3.46 | 1.28 | 0.41 | |||
Effect of Pedalitin treatment on gene UreC of Proteus mirabilis using qPCR.
| S. NO | Treatment group | Target urease | House Keeping | References | Mean | SEM | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Pedalitin | 17.69 | D12 | SYBR | 16srRNA | 14.78 | 2.91 | 0.90 | 0.53 | 0.62 ± 0.11 | 0.0413272 | |
| Pedalitin | 17.17 | E12 | SYBR | 16srRNA | 14.81 | 2.36 | 0.34 | 0.79 | |||
| Pedalitin | 17.47 | F12 | SYBR | 16srRNA | 14.91 | 2.55 | 0.83 | 0.56 | |||
| Pedalitin | 17.66 | G12 | SYBR | 16srRNA | 14.98 | 2.69 | 0.94 | 0.52 | |||
| Pedalitin | 17.65 | C12 | SYBR | 16srRNA | 14.77 | 2.89 | 0.95 | 0.52 | |||
| Pedalitin | 17.87 | H12 | SYBR | 16srRNA | 15.06 | 2.80 | 0.84 | 0.56 | |||
| Pedalitin | 17.01 | A12 | SYBR | 16srRNA | 14.81 | 2.20 | 0.34 | 0.79 | |||
| Pedalitin | 17.77 | B12 | SYBR | 16srRNA | 15.04 | 2.73 | 0.54 | 0.69 | |||